Skip to main content

Table 4 Direct health care annual costs (2015 USD)

From: Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes

  Average annual costs References
Health care costs (per episode/year)
 Myocardial infarction $18627 Bergenheim et al., 2012 [12]
 Heart failure $14118 Bergenheim et al., 2012 [12]
 Stroke $7939 Bergenheim et al., 2012 [12]
 Hypoglycemia events requiring medical assistance $199 Bergenheim et al., 2012 [12]
 Severe hypoglycemia event $146 Bergenheim et al., 2012 [12]
 Weight gain $289 Bergenheim et al., 2012 [12]
Drug cost (per patient/year)
 Metformin, generic drug $24 NADAC (January 2015) [22]
 Dipeptidyl peptidase-4 inhibitor, brand $3500 ($3401; $3599) NADAC (January 2015) [22]
 Sulfonylurea (glipizide), generic $16 NADAC (January 2015) [22]
 Insulin glargine, brand $3646 NADAC (January 2015) [22]
  1. All drug costs and direct health-state costs were expressed in 2015 US dollars ($) per patient/year